81265-93-2

Usage

Uses

Used in Molecular Biology Research:
5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is used as a fluorescent label for DNA and RNA molecules, allowing for the detection and analysis of these nucleic acids in various experimental setups. Its fluorescent properties enable researchers to monitor the hybridization, folding, and interactions of nucleic acids with other molecules, providing valuable insights into their structure and function.
Used in Synthetic Oligonucleotide Synthesis:
In the synthesis of synthetic oligonucleotides, 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine serves as a building block for the assembly of custom-designed sequences. The presence of the DMT group at the 5' end facilitates the coupling of the compound to other nucleotides during the solid-phase synthesis process, while the TBDMS group at the 2' position protects the hydroxyl group from unwanted reactions. The benzoyl group on the nitrogen atom further enhances the stability of the compound during synthesis.
Used in Diagnostic Applications:
5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine is also employed in the development of diagnostic assays and tests, where its fluorescent properties can be harnessed to detect specific DNA or RNA sequences associated with diseases or conditions. By incorporating 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine into probes or primers, researchers can design highly sensitive and specific diagnostic tools for various applications, including infectious disease detection, genetic testing, and environmental monitoring.
Used in Drug Discovery and Development:
The unique properties of 5'-O-DMT-2'-O-TBDMS-N-Bz-Adenosine make it a valuable tool in the field of drug discovery and development. Its ability to interact with nucleic acids can be exploited to design molecules that target specific genes or regulatory elements, potentially leading to the development of new therapeutic agents for a wide range of diseases. Additionally, its fluorescent properties can be used to monitor the binding and activity of these molecules in cellular and animal models, aiding in the optimization of their efficacy and safety.

Upstream product

• 129666-75-7 6-N-benzoyl-5'-O-(4,4'-dimethoxytrityl)adenosine 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 4546-55-8 N-benzoyladenosine 
• 1348775-39-2 adenosine 
• 98-88-4 benzoyl chloride 
• 58-61-7 adenosine 
• 401812-98-4 3’,5’-O-bis(t-butylsilyl)-2’-O-(t-butyldimethylsilyl)-N6-benzoyladenosine 
• 212375-93-4 3’,5’-O-bis(t-butylsilyl)-2’-O-(t-butyldimethylsilyl)adenosine 
• 97219-09-5 3',5'-O-(Di-tert-butylsilanediyl)adenosine 
• 69504-07-0 N⁶-benzoyl-2'-O-(tert-butyldimethylsilyl)adenosine 

Downstream Products

• 81279-42-7 5'-dimethoxytrityl 2'-tert-butyldimethyl silyl N-benzoyladenosine 3'-p-chlorophenyl β-cyanoethyl phosphotriester 
• 131316-88-6 Succinic acid mono-[(2R,3R,4R,5R)-5-(6-benzoylamino-purin-9-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-3-yl] ester 
• 1374755-65-3 C₅₇H₆₅N₆O₈PS₂Si 
• 127553-42-8 5'-O-DMTr-2'-O-TBDMS-N-Bz-adenosine-3'-O-(2-chlorophenyl)phosphate triethylammonium salt 
• 118380-97-5 C₄₇H₅₈N₇O₁₃PSi*H₃N 
• 222725-68-0 N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-((tert-butyldimethylsilyl)oxy)-4-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 222725-66-8 N-{9-[5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-(tert-butyl-dimethyl-silanyloxy)-4-oxo-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide 
• 104992-55-4 N⁶-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldimethylsilyl)adenosine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) 
• 136044-34-3 N⁶-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldimethylsilyl)adenosine 3'-O-(2-cyanoethyl N,N-diethylphosphoramidite) 
• 160056-44-0 C₁₀H₁₃N₅O₄SiC₆H₁₄PO₃HC(C₆H₅)3C₂H₃O₂C₇H₄C₆H₄ 
• 100638-43-5 Phosphoric acid (2R,3R,4R,5R)-5-(6-benzoylamino-purin-9-yl)-4-(tert-butyl-dimethyl-silanyloxy)-2-hydroxymethyl-tetrahydro-furan-3-yl ester 4-chloro-phenyl ester 2-cyano-ethyl ester 

Relevant academic research and scientific papers

CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF

Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.

CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING

Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

Practical silyl protection of ribonucleosides

Herein we report the site-selective silylation of the ribonucelosides. The method enables a simple and efficient procedure for accessing suitably protected monomers for automated RNA synthesis. Switching to the opposite enantiomer of the catalyst allows f

Synthesis of 2'-O-substituted ribonucleosides.

An efficient synthesis of 2'-O-substituted ribonucleosides, including 2'-O-TBDMS and 2'-O-TOM protected as well as 2'-O-Me and 2'-O-allyl derivatives is presented. Di-t-butylsilylene group was employed for simultaneous protection of 3'- and 5'- hydroxyl functions of nucleoside on the first step. Subsequent silylation or alkylation of free 2'-OH followed by introduction of suitable protection on the base moiety and removal of cyclic silyl protection gave target compounds in a high yield.

Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives

The present invention provides methods for the chemical synthesis of nucleosides and derivatives thereof, including 2′-amino, 2′-N-phthaloyl, 2′-O-methyl, 2′-O-silyl, 2′OH nucleosides, C-nucleosides, nucleoside phosphoramidites, C-nucleoside phosphoramidites, and non-nucleoside derivatives.

Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives

The present invention provides methods for the chemical synthesis of nucleosides and derivatives thereof, including 2′-amino, 2′-N-phthaloyl, 2′-O-methyl, 2′-O-silyl, 2′-O-triisopropylsilyloxymethyl, 2′-OH nucleosides, C-nucleosides, nucleoside phosphoramidites, C-nucleoside phosphoramidites, and non-nucleoside derivatives.

An efficient preparation of protected ribonucleosides for phosphoramidite RNA synthesis

An efficient synthesis of protected ribonucleosides useful for phosphoramidite RNA synthesis is described. Di-t-butylsilylene group was employed for simultaneous protection of 3′- and 5′-hydroxyl functions of nucleoside. Subsequent silylation of free 2′-O

Modified phosphotriester method for chemical synthesis of ribooligonucleotides. Part I. Synthesis of riboundecaadenylate and two fragments constituting the sequence of R-17 translation control signal

A modified phosphotriester method has been succesfully applied for the chemical synthesis of ribooligonucleotides.The starting material is a fully protected ribomononucleoside containing a 3'-phosphotriester group 5.The coupling reaction is performed usin